Skip to main content

Table 1 Patient demographics

From: Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study

  Patients (n = 59) Courses (n = 475)
Gender (male/female) 33/26 307/168
Age, median (range) 69 (38–84) 69 (38–84)
Albumin (g/dL) 4 (3.7–4.2) 4 (3.7–4.2)
Aspartate aminotransferase (U/L) 24 (19–30) 25 (19–33)
Alanine aminotransferase (U/L) 21 (15–28.5) 20 (14–29)
Serum creatinine (mg/dL) 0.61 (0.51–0.76) 0.63 (0.52–0.80)
Total bilirubin (mg/dL) 0.5 (0.4–0.7) 0.5 (0.4–0.6)
C-reactive protein (CRP, mg/dL) 0.3 (0.06–1.13) 0.22 (0.08–0.65)
Neutrophils (/μL) 2570 (1735–3298) 2510 (1760–3480)
White blood cells (/μL) 4250 (3155–5255) 4400 (3485–5905)
Hemoglobin (g/dL) 10.6 (9.9–11.5) 10.6 (9.7–116)
Platelets (/μL) 17.5 (12.6–26.1) 18.95 (12.9–29.3)
Neutrophil/lymphocyte ratio (NLR) 1.91 (1.41–3.18) 1.99 (1.39–3.12)
Modified Glasgow prognostic score (mGPS, 0/1/2) 43/9/7 376/58/21
Carcinoembryonic antigen (CEA, ng/mL) 6.2 (2.7–9.7) 4.6 (2.8–8.3)
Carbohydrate antigen 19–9 (CA19–9, U/mL) 655.1 (54.0–2691) 166.1 (39.8–1228)
Chemotherapy, N (%)
 FOLFIRINOX 20 (33.9%) 179 (37.7%)
 Gemcitabine plus nab-paclitaxel (GnP) 27 (45.8%) 227 (47.8%)
 Gemcitabine monotherapy 12 (20.3%) 69 (14.5%)
Chemotherapy setting, N (%)
 1st line chemotherapy 44 (74.6%) 378 (79.6%)
 2nd line chemotherapy 10 (16.9%) 68 (14.3%)
 3rd line chemotherapy 2 (3.4%) 13 (2.7%)
 Preoperative adjuvant chemotherapy 1 (1.7%) 14 (2.9%)
 Postoperative adjuvant chemotherapy 2 (3.4%) 2 (0.4%)
Time from start of first-line chemotherapy (days) 71 (35.5–253.5) 220 (112–386)
Distant metastasis, N (%) 43 (72.9%) 356 (74.9%)
Recurrent cancer, N (%) 15 (25.4%) 155 (32.6%)
  1. All data indicate median, inter-quartile range (25–75th percentiles) unless otherwise indicated